OPRI’s inaugural R&D program within Singapore focuses on ‘’Uncontrolled & Severe Asthma: Novel Risk & Therapeutic Response Prediction – Maximising the Value of Future Interventions’’ commenced in 2015, in consultation with its affiliate research unit in the UK. The objectives of the program are defined as follows:
- acquiring new knowledge within the field of uncontrolled and severe asthma through conducting novel systematic, investigative and experimental (SIE) studies
- enabling the creation of new therapeutic strategies and novel risk prediction processes which address the current burden of uncontrolled and severe asthma in Singapore and globally and to maximize the value of future interventions
- informing the improvement of existing therapeutic strategies or processes to address the current burden of uncontrolled and severe asthma in Singapore and globally and to maximize the value of future interventions
In order to meet the program objectives, leading professionals within the field have prioritised three key research themes/projects which were based on the scientific challenges that need to be overcome in order to acquire new knowledge that informs the creation of new products or processes; or improves existing products or processes. These are summarised below:
- Inhaler Device Research: research to aid the development of novel & innovative inhaler devices
- Severe Asthma Research: research to aid the development of novel precision medicine therapies
- Biomarkers Research: research to aid the development of novel risk prediction tools
| Research & Development Program
Uncontrolled & Severe Asthma: Novel Risk & Therapeutic Response Prediction |
|||
| R&D Themes | SIE Acitivites | Duration | R&D Country |
| Inhaler Devices | CRITical Inhaler mistaKes and Asthma control (CRITIKAL) | 2014-2017 | SG |
| Health Care Professional Easy Low Instruction Over Time (HCP ELIOT) | 2014-2018 | SG | |
| Device Adherence Study Group (DASG) | 2015-2019 | SG | |
| Biomarkers | Non-Specific Respiratory Symptoms (NSRS) | 2013-2017 | SG |
| To be assigned (TBA) | |||
| Severe Asthma | Impact of exacerbation burden on lung function trajectory | 2017-2023 | SG |
| Assess the overlap of collected biomarkers in severe asthma | 2017-2023 | SG | |
| Define a consensus-based definition of a severe asthma ‘super-responder’ | 2019- | SG | |